TerminatedPhase 2NCT00113828

Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Thomas Spitzer, M.D.
Massachusetts General Hospital, Harvard University
Intervention
Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant(procedure)
Enrollment
5 enrolled
Eligibility
18-65 years · All sexes
Timeline
20042007

Study locations (1)

Collaborators

Dana-Farber Cancer Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00113828 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials